Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 837-842

  Molina, I ^a   Falco V ^a   Crespo, M ^a   Riera, C ^b   Ribera, E ^a   Curran, A ^a   Carrio, J ^b   Diaz, M ^a   Villar del saz, S ^a   Fisa, R ^b   Lopez Chejade P ^b   Ocana I ^a   Pahissa, A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

AIDS; AMB; Infections; Opportunities

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CD4 ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; MALE; OUTCOMES RESEARCH; PROBABILITY; RELAPSE; SECONDARY PREVENTION; SURVIVAL RATE; TIME; VISCERAL LEISHMANIASIS;

ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CD4 LYMPHOCYTE COUNT; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34548740143     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm294     Document Type: Article

References (36)

1. Alvar J, Cañavate C, Gutiérrez-Solar B et al. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Microbiol Rev 1997; 10: 298-319.
2. Mira JA, Corzo JE, Rivero A et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70: 298-301.
3. Fernández-Cotarello MJ, Martínez Abellan J, Vales Guerra JM et al. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2003; 37: 973-7.
4. Ribera E, Ocaña I, de Otero J et al. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus infected patients. Am J Med 1996; 100: 496-501.
5. Pasquau F, Ena J, Sanchez R et al. Leishmaniasis as an opportunistic infection in HIV-Infected patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. Eur J Clin Microbiol Infect Dis 2005; 24 411-8.
6. Riberia E, Cucurull E, Ocana I et al. Visceral leishmaniasis in patients with HIV infection. Enferm Infecc Microbiol Clin 1995; 13: 73-9.
7. De la Rosa R, Pineda JA, Delgado J et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40 762-7.
8. De la Rosa R, Pineda JA, Delgado J et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32: 633-5.
9. López-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are coinfected with HIV. Ann Trop Med Parasitol 2002; 97: S143-7.
10. Casado JL, Vélez López R, Pintado V et al. Relapsing visceral leishmaniasis in HIV-Infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20: 202-5.
11. Berenguer J, Cosin J, Miralles P et al. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients undergoing successful protease inhibitor therapy. AIDS 2000; 14 2946-8.
12. Angarano G, Maggi P, Coppola SL et al. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1998; 17: 365-7.
13. Lafeuillade A, Chaffanjon P, Delbeke E et al. Maintenance itraconazole for visceral leishmaniasis in HIV infection. Am J Med 1992; 92: 449.
14. Raffi F, Merrien D, Le Pape P et al. Use of an itraconazole/ allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Clin Infect Dis 1995; 21: 1338-9.
15. Torrus D, Boix V, Massa B et al. Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother 1996; 37: 1042-3.
16. Derouin F, Gangneux JP. Changing patterns of disease and treatment of parasitic opportunistic infections. Curr Opin Infect Dis 1998; 11: 711-6.
17. Perez-Molina JA, Lopez-Velez R, Montilla P et al. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS 1996; 10: 237-8.
18. Hamour AA, Skelly R, Jowitt SN et al. Visceral leishmaniasis (Kala-azar) in two patients with HIV-1 infection: Atypical features and response to therapy. J Infect 1998; 36: 217-20.
19. Laguna F, Adriados M, Alvar J et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16: 898-903.
20. López-Vélez R, Videla S, Márquez M et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53: 540-3.
21. Mastroianni CM, d'Ettorre G, Forcina G et al. Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: Report of two cases. J Infect 2000; 40: 94-6.
22. Borrelli P, Imperato A, Murdaca G et al. Liposomal amphotericin B as first line. and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV. Ann Ital Med Int 2000; 15: 169-71.
23. Murdaca G, Setti M, Campelli A et al. Liposomal amphotericin B for treatment of acute phase and secondary prophylaxis of visceral leishmaniasis in a HIV positive patient. Infez Med 2000; 8: 241-4.
24. Orlando G, Del Sorbo F, Corbellino M et al. Secondary prophylaxis for Leishmania infection in an HIV-positive patient. AIDS 1998; 12: 2086-7.
25. Lopez Dupla M, Gil Aguado A, Uriol Lavilla P et al. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmianiasis in HIV infected patients: Report of two cases. J Antimicrob Chemother 1993; 32: 657-9.
26. Montana M, Chochol N, Monges P et al. Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: Report of five clinical cases. Pathol Biol 2004; 52 66-75.
27. Lazanas MC, Tsekes GA, Papandreou S et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7: 1018-9.
28. MacBride M, Linney M, Claydon EJ et al. Visceral leishmaniasis following treatmentwith liposomal amphotericin B. Clin Infect Dis 1994; 19: 362.
29. Barratt G, Legrand P. Comparison of the efficacy and pharmacology of formulations of amphotericin B used In treatment of leishmaniasis. Curr Opin Infect Dis 2005; 18: 527-30.
30. Riera C, Fisa R, Ribera E et al. Value of culture and nested PCR of blood in prediction of relapses in patients co-infected with Leishmania and human immunodeficiency, virus. Am J Trop Med Hyg 2005; 73: 1012-5.
31. Berhe N, Wolday A, Hailu Y et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999; 13: 1921-5.
32. Murray HW, Oca MJ, Granger AM et al. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection experimental visceral leishmaniasis. J Clin Invest 1989; 83: 1253-7.
33. Murray HW, Oca MJ, Granger AM. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: Response to amphotericin B and pentamidine. Antimicrob Agents Chemother 1993; 37: 1504-5.
34. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania dovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-5.
35. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-26.
36. Carrió J, Riera C, Ribera E et al. In vitro susceptibility of Leishmania strains isolated from HIV coinfected patients to liposomal amphotericin B and pentavalent antimony (oral communication). In: Programme of the Third World Congress on Leishmaniasis, Palermo, Sicily, 2005, p. 128.